Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 6 | 2015 | 91 | 0.630 |
Why?
|
| Liver | 3 | 2008 | 184 | 0.520 |
Why?
|
| Fatty Liver | 2 | 2004 | 31 | 0.450 |
Why?
|
| Colonoscopy | 5 | 2015 | 53 | 0.390 |
Why?
|
| Early Detection of Cancer | 5 | 2015 | 89 | 0.370 |
Why?
|
| Antioxidants | 2 | 2008 | 65 | 0.270 |
Why?
|
| Coffee | 1 | 2006 | 4 | 0.260 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 24 | 0.260 |
Why?
|
| Caffeine | 1 | 2006 | 66 | 0.260 |
Why?
|
| Body Constitution | 1 | 2004 | 3 | 0.240 |
Why?
|
| Vitamin D Deficiency | 1 | 2004 | 7 | 0.240 |
Why?
|
| Obesity | 2 | 2004 | 307 | 0.240 |
Why?
|
| Vitamin D | 1 | 2004 | 42 | 0.230 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2004 | 1 | 0.230 |
Why?
|
| Liver Failure | 1 | 2004 | 11 | 0.230 |
Why?
|
| Peptide Hormones | 1 | 2003 | 5 | 0.230 |
Why?
|
| Leptin | 1 | 2003 | 24 | 0.230 |
Why?
|
| Dietary Supplements | 1 | 2004 | 63 | 0.220 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 39 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 135 | 0.220 |
Why?
|
| Energy Metabolism | 1 | 2003 | 54 | 0.220 |
Why?
|
| Immune System | 1 | 2003 | 26 | 0.220 |
Why?
|
| Plant Extracts | 2 | 2008 | 17 | 0.220 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 26 | 0.220 |
Why?
|
| Enteral Nutrition | 1 | 2003 | 56 | 0.210 |
Why?
|
| Perioperative Care | 1 | 2003 | 56 | 0.210 |
Why?
|
| Adenomatous Polyps | 2 | 2013 | 3 | 0.210 |
Why?
|
| Celiac Disease | 1 | 2002 | 9 | 0.200 |
Why?
|
| Colonic Polyps | 2 | 2013 | 26 | 0.200 |
Why?
|
| Adenoma | 2 | 2013 | 46 | 0.200 |
Why?
|
| Gastritis | 1 | 2002 | 3 | 0.200 |
Why?
|
| Helicobacter pylori | 1 | 2002 | 4 | 0.200 |
Why?
|
| Helicobacter Infections | 1 | 2002 | 3 | 0.200 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 13 | 0.200 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 35 | 0.200 |
Why?
|
| DNA Methylation | 2 | 2013 | 134 | 0.200 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 32 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 74 | 0.190 |
Why?
|
| Calcium | 2 | 2004 | 503 | 0.190 |
Why?
|
| Humans | 24 | 2015 | 30997 | 0.190 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 217 | 0.190 |
Why?
|
| Pain | 1 | 2004 | 426 | 0.190 |
Why?
|
| Mass Screening | 2 | 2015 | 186 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 206 | 0.130 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 1 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 29 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2015 | 11 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 8 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2015 | 68 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2014 | 20 | 0.120 |
Why?
|
| Vaccination | 1 | 2014 | 48 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2014 | 13 | 0.120 |
Why?
|
| Barrett Esophagus | 1 | 2014 | 12 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2015 | 158 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 16 | 0.110 |
Why?
|
| Intestines | 1 | 2014 | 115 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2014 | 123 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 90 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 155 | 0.100 |
Why?
|
| Middle Aged | 10 | 2015 | 10195 | 0.100 |
Why?
|
| Male | 12 | 2015 | 16445 | 0.100 |
Why?
|
| Female | 12 | 2015 | 16983 | 0.100 |
Why?
|
| Disease Progression | 2 | 2004 | 830 | 0.090 |
Why?
|
| Aged | 8 | 2015 | 10048 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 404 | 0.080 |
Why?
|
| Cynara scolymus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Phenols | 1 | 2008 | 8 | 0.080 |
Why?
|
| Flavonoids | 1 | 2008 | 21 | 0.080 |
Why?
|
| Rats | 3 | 2008 | 873 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2005 | 991 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2008 | 134 | 0.070 |
Why?
|
| Energy Intake | 2 | 2004 | 73 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 121 | 0.070 |
Why?
|
| Adult | 6 | 2014 | 8931 | 0.070 |
Why?
|
| Duodenal Diseases | 1 | 2005 | 6 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 19 | 0.060 |
Why?
|
| Lung Transplantation | 1 | 2005 | 18 | 0.060 |
Why?
|
| Abdomen | 1 | 2004 | 11 | 0.060 |
Why?
|
| Osteomalacia | 1 | 2004 | 1 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 54 | 0.060 |
Why?
|
| Developing Countries | 1 | 2004 | 21 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2015 | 2043 | 0.060 |
Why?
|
| Diet | 2 | 2004 | 194 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2004 | 3 | 0.060 |
Why?
|
| Short Bowel Syndrome | 1 | 2004 | 2 | 0.060 |
Why?
|
| Ergocalciferols | 1 | 1984 | 2 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1984 | 6 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 1 | 2004 | 4 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1984 | 19 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 147 | 0.060 |
Why?
|
| Ghrelin | 1 | 2003 | 3 | 0.060 |
Why?
|
| Neuropeptide Y | 1 | 2003 | 3 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 156 | 0.060 |
Why?
|
| Food, Organic | 1 | 2003 | 3 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2003 | 7 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 29 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 64 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2004 | 81 | 0.050 |
Why?
|
| Body Weight | 1 | 2003 | 141 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 409 | 0.050 |
Why?
|
| Diet, Fat-Restricted | 1 | 2002 | 7 | 0.050 |
Why?
|
| Insulin | 1 | 2003 | 97 | 0.050 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genistein | 1 | 2002 | 3 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vacuoles | 1 | 2002 | 6 | 0.050 |
Why?
|
| Caco-2 Cells | 1 | 2002 | 55 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2002 | 68 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 344 | 0.050 |
Why?
|
| Cell Survival | 1 | 2002 | 164 | 0.050 |
Why?
|
| Length of Stay | 1 | 2003 | 339 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2015 | 3658 | 0.050 |
Why?
|
| Animals | 3 | 2008 | 4723 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2013 | 662 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 583 | 0.050 |
Why?
|
| Prognosis | 2 | 2013 | 919 | 0.040 |
Why?
|
| Mice | 1 | 2003 | 1683 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2005 | 3806 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2015 | 14 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 23 | 0.030 |
Why?
|
| Risk Factors | 1 | 2002 | 2588 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 16 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 11 | 0.030 |
Why?
|
| Stomach | 1 | 2014 | 19 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 324 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 74 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 80 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2014 | 91 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 49 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 70 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 249 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 511 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 549 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 500 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5189 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 873 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 81 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 66 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 943 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1009 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 733 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 241 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 817 | 0.020 |
Why?
|
| Colon | 1 | 2011 | 163 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1922 | 0.020 |
Why?
|
| United States | 1 | 2015 | 2375 | 0.020 |
Why?
|
| Glucose Oxidase | 1 | 2008 | 1 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2008 | 1 | 0.020 |
Why?
|
| Phenylenediamines | 1 | 2008 | 1 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 9 | 0.020 |
Why?
|
| Polyphenols | 1 | 2008 | 5 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 44 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 178 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1897 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 204 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 272 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 442 | 0.020 |
Why?
|
| Apoptosis | 1 | 2008 | 260 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 686 | 0.020 |
Why?
|
| Duodenoscopy | 1 | 2005 | 2 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2005 | 51 | 0.020 |
Why?
|
| Forecasting | 1 | 2005 | 114 | 0.010 |
Why?
|
| Body Water | 1 | 2004 | 4 | 0.010 |
Why?
|
| Dehydration | 1 | 2004 | 4 | 0.010 |
Why?
|
| Gastrostomy | 1 | 2004 | 8 | 0.010 |
Why?
|
| Rehydration Solutions | 1 | 2004 | 4 | 0.010 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 1984 | 3 | 0.010 |
Why?
|
| Phosphorus | 1 | 1984 | 5 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1984 | 24 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 2004 | 35 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2004 | 34 | 0.010 |
Why?
|
| Random Allocation | 1 | 1984 | 147 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1984 | 126 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 428 | 0.010 |
Why?
|
| Exercise | 1 | 2002 | 507 | 0.010 |
Why?
|